BioCentury | Nov 9, 2015
Clinical News

CAR-T CD20: Phase IIa data

...Chinese Phase IIa trial in 10 patients with CD20-positive advanced B cell NHL showed that CBM-CD20.1...
...80%, including 5 complete remissions and 3 partial remissions, plus 2 cases of stable disease. CBM-CD20.1...
...Translational Medicine in Baltimore. Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Product: CAR-T CD20 ( CBM-CD20.1...
BioCentury | Apr 6, 2015
Clinical News

CAR-T CD20: Clinical trial data

...An open-label, Chinese clinical trial in 7 patients with CD20-positive chemotherapy-refractory advanced DLBCL showed that CAR-T CD20...
...achieved 6-month tumor regression. Cellular Biomedicine Group Inc . (NASDAQ:CBMG), Palo Alto, Calif. Product: CAR-T CD20 (CBM-CD20.1...
Items per page:
1 - 2 of 2